Gotham Asset Management LLC Purchases New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)

Gotham Asset Management LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) in the fourth quarter, Holdings Channel.com reports. The firm purchased 3,545 shares of the biotechnology company’s stock, valued at approximately $309,000.

Other institutional investors have also made changes to their positions in the company. R Squared Ltd bought a new position in shares of Blueprint Medicines in the fourth quarter valued at about $51,000. Headlands Technologies LLC bought a new position in shares of Blueprint Medicines in the fourth quarter valued at about $65,000. Thematics Asset Management bought a new position in shares of Blueprint Medicines in the fourth quarter valued at about $72,000. Covestor Ltd raised its holdings in shares of Blueprint Medicines by 62.7% in the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 375 shares during the last quarter. Finally, Asset Management One Co. Ltd. bought a new position in shares of Blueprint Medicines in the fourth quarter valued at about $88,000.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $103.00 on Wednesday. The firm has a market capitalization of $6.65 billion, a P/E ratio of -95.37 and a beta of 0.83. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The business has a 50-day moving average of $90.13 and a 200-day moving average of $94.53. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Blueprint Medicines’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.40 earnings per share. On average, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,752 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the transaction, the insider now directly owns 16,944 shares in the company, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the completion of the transaction, the chief operating officer now owns 66,992 shares of the company’s stock, valued at $6,816,436. This represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,503 shares of company stock worth $1,027,931. 4.21% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BPMC shares. Scotiabank began coverage on Blueprint Medicines in a report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 price target for the company. Piper Sandler lifted their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating for the company. Needham & Company LLC lowered their price objective on Blueprint Medicines from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, April 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research report on Thursday, May 1st. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.56.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.